Dalargin: nasal respiratory-infection use and formulation — EP3556377B1
Evgeny Alexandrovich Chertorizhsky, Mikhail Vladimirovich Ovchinnikov, Aleksey Viktorovich Kleimenov · 2021 · EP3556377B1 · patent family 64328036
Published 2021-09-08.
Reported patent results
Narrative findings; numerical extraction incomplete
The patent reports reduced stimulated inflammatory-cytokine production and altered innate-cell activity.
Dalargin preclinical immune/inflammatory experiments, including cells from 20 healthy donors; these donors did not receive the proposed treatment.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Donor-cell cytokines | Reduced stimulated IL-1, IL-6 and TNF-α production reported | In-vitro experiment using cells from 20 donors; exact figure percentages not transcribed |
| Animal innate-cell findings | Increased phagocytic activity described; no detected difference between the tested routes | A laboratory result, not demonstrated clinical infection recovery |
Human-derived cells are not a human treatment trial. Cytokine and cell-function results cannot establish clinical antiviral effectiveness, route equivalence or safety.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Formulation. The patent concerns nasal Dalargin compositions and proposed respiratory-infection applications.
A granted formulation or use claim does not establish clinical antiviral benefit.
- Publication
- EP3556377B1 ↗ · 2021-09-08
- Earliest priority / filing
- 2018-04-18 / 2019-04-10
- Original applicant / assignee
- PVP Labs Pte Ltd
- Indexed status
- Active · checked 2026-11-06
- Patent family
- 64328036 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Dalargin for use in the treatment of acute respiratory viral infections
Inventors: Evgeny Alexandrovich Chertorizhsky; Mikhail Vladimirovich Ovchinnikov; Aleksey Viktorovich Kleimenov.
EP3556377B1 · US11365216B2 · JP6952379B2 · KR20200132931A · CN112020367B · CA3093492C · EA037430B1 · ES2901193T3 · HRP20211906T1 · HUE056471T2 · MY206814A · PH12020551709A1 · PL3556377T3 · PT3556377T · RS62632B1 · RU2672888C1 · SG11202009591PA · WO2019202380A1 · ZA202006656B
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- A granted formulation or use claim does not establish clinical antiviral benefit.
- Human-derived cells are not a human treatment trial. Cytokine and cell-function results cannot establish clinical antiviral effectiveness, route equivalence or safety.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-64328036. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Evgeny Alexandrovich Chertorizhsky, Mikhail Vladimirovich Ovchinnikov, Aleksey Viktorovich Kleimenov. Dalargin: nasal respiratory-infection use and formulation — EP3556377B1 EP3556377B1 · patent family 64328036 2021.
Molekul research summary: https://molekul.io/research/patent-ep3556377b1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry